Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Zhejiang UniversityActive in the last 2 years

Ri‐Sheng Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0554-9484; OpenAlex author ID A5080959496. Sources: ClinicalTrials.gov.

Their work

Papers
13 (first author 0, last author 8)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2012: 1 trial · 2013: none · 2014: none · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 13

  1. Spatiotemporally controlled ferritin-targeting PROTAC nanoplatform for visualized manipulation of endogenous "Iron pool" in pancreatic cancer therapy. Last author DOI 10.1016/j.mtbio.2025.102661↗
  2. Recent Advances in Nanotechnology-Based Approaches for Ferroptosis Therapy and Imaging Diagnosis in Pancreatic Cancer. Last author DOI 10.3390/pharmaceutics17070937↗
  3. Differentiating small (< 2 cm) pancreatic ductal adenocarcinoma from neuroendocrine tumors with multiparametric MRI-based radiomic features. Last author DOI 10.1007/s00330-024-10837-x↗
  4. A collagenase-decorated Cu-based nanotheranostics: remodeling extracellular matrix for optimizing cuproptosis and MRI in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12951-024-02968-6↗
  5. Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma. Last author DOI 10.3390/molecules28031506↗
  6. Extracellular matrix modulating enzyme functionalized biomimetic Au nanoplatform-mediated enhanced tumor penetration and synergistic antitumor therapy for panc… Last author DOI 10.1186/s12951-022-01738-6↗
  7. Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer. Co-author DOI 10.1002/jmri.27024↗
  8. Grade 3 Pancreatic Neuroendocrine Tumors on MDCT: Establishing a Diagnostic Model and Comparing Survival Against Pancreatic Ductal Adenocarcinoma. Last author DOI 10.2214/ajr.19.21921↗
  9. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. Co-author DOI 10.1634/theoncologist.2018-0696↗
  10. Targeting Pancreatic Cancer Cells with Peptide-Functionalized Polymeric Magnetic Nanoparticles. Co-author DOI 10.3390/ijms20122988↗
  11. [Accurate imaging diagnosis and evaluation of pancreatic cancer]. Last author DOI 10.3785/j.issn.1008-9292.2017.10.02↗
  12. Pancreatic cancer adjuvant radiotherapy target volume design: based on the postoperative local recurrence spatial location. Co-author DOI 10.1186/s13014-016-0714-7↗
  13. [Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China]. Co-author DOI 10.3760/cma.j.issn.0529-5815.2016.04.006↗

Trials 1

  1. Related Studies of Imaging Features and Prognosis Between Pancreatic Neuroendocrine Tumors and Pancreatic Cancer Principal investigator NCT04977596↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaoyan Yang · 4 shared papers, 2023–2026 · strength 1.06
  2. Yining Wang · 3 shared papers, 2024–2026 · strength 0.82
  3. Weilin Wang · 1 shared paper, 2026 · strength 0.30
  4. Tingbo Liang · 4 shared papers, 2016–2020 · strength 0.27
  5. Keren Shen · 1 shared paper, 2024 · strength 0.26
  6. Yao Pan · 2 shared papers, 2017–2020 · strength 0.22
  7. Risheng Que · 3 shared papers, 2016–2020 · strength 0.22
  8. Jiayi Chen · 1 shared paper, 2024 · strength 0.19
  9. Guping Tang · 1 shared paper, 2024 · strength 0.19
  10. Qichun Wei · 3 shared papers, 2016–2019 · strength 0.18
  11. Xueli Bai · 3 shared papers, 2016–2019 · strength 0.18
  12. Xiang Li · 2 shared papers, 2019–2020 · strength 0.16
  13. Qi Zhang · 2 shared papers, 2019–2020 · strength 0.16
  14. Yinan Shen · 2 shared papers, 2019–2020 · strength 0.16
  15. Xiaoyan Yang · 1 shared paper, 2022 · strength 0.15
  16. Jianying Lou · 2 shared papers, 2016–2019 · strength 0.13
  17. Haiyan Chen · 1 shared paper, 2020 · strength 0.11
  18. Xiuliang Zhu · 1 shared paper, 2019 · strength 0.09
  19. Zuhua Wang · 1 shared paper, 2019 · strength 0.09
  20. Xiaozhen Zhang · 1 shared paper, 2020 · strength 0.09
  21. Mengyi Lao · 1 shared paper, 2020 · strength 0.09
  22. Wei Chen · 1 shared paper, 2020 · strength 0.09
  23. Tianyu Tang · 1 shared paper, 2020 · strength 0.09
  24. Xueli Bai · 1 shared paper, 2020 · strength 0.09
  25. Ying Yuan · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.